TYMS upregulation in SCLC, while contributing to resistance to conventional TS inhibitors, may indicate a reliance on de novo Thy biosynthesis in SCLC that renders this malignancy susceptible to treatment with polymeric fluoropyrimidines, such as CF10, that are more directly converted to FdUMP. This evidence concerns the gene TYMS and small cell lung carcinoma.